Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 12,508 matching trials from the live ClinicalTrials.gov search.
Filters: Miami, Florida Clear all
Completed Phase 2 Interventional

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

NCT00344227
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Lucentis (Ranibizumab)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2006 · Synced Oct 31, 2026, 9:35 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

NCT02951988
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo-matching Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
137
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 31, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

NCT00637403
View directory record Official record
Conditions
Healthy
Interventions
Megestrol acetate concentrated suspension 125 mg/mL
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 31, 2026, 9:35 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

NCT06632327
View directory record Official record
Conditions
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
415
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT03748186
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
STRO-002
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

NCT05553470
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 31, 2026, 9:35 AM EDT
Completed No phase listed Observational

Study of Pediatric Migraine: The Pediatric Migraine Registry

NCT03742024
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
4 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
San Francisco, California • Colorado Springs, Colorado • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00039962
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 31, 2026, 9:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HealthSpark: Health Access for Children in Federally-Subsidized Child Care

NCT00339027
View directory record Official record
Conditions
Asthma, Obesity, ADHD
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
3 Years to 5 Years
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 31, 2026, 9:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441
View directory record Official record
Conditions
Vitreomacular Adhesion Including Macular Hole
Interventions
Ocriplasmin, Sham injection
Drug · Other
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

NCT03393013
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Upland, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 31, 2026, 9:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
View directory record Official record
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 31, 2026, 9:35 AM EDT
Recruiting Phase 3 Interventional

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

NCT06911424
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Fusidic Acid 1%, Placebo
Drug
Lead sponsor
Baxis Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
38
States / cities
Little Rock, Arkansas • Huntington Beach, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246
View directory record Official record
Conditions
Gout
Interventions
lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 31, 2026, 9:35 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

NCT05603910
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy
Drug · Radiation
Lead sponsor
Aaron Wolfson
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

NCT00822120
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
423
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 31, 2026, 9:35 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL

NCT01278420
View directory record Official record
Conditions
Cataract
Interventions
Tecnis MF, ReSTOR
Device
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Santa Barbara, California • Boynton Beach, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS-SR 50 mg, DVS-SR 100 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Beverly Hills, California • Northridge, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 31, 2026, 9:35 AM EDT
Terminated Phase 2Phase 3 Interventional

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

NCT04360096
View directory record Official record
Conditions
SARS-CoV 2, COVID, ARDS, ALI, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Dyspnea
Interventions
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo
Drug · Device
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 31, 2026, 9:35 AM EDT
Completed Not applicable Interventional Results available

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

NCT00435942
View directory record Official record
Conditions
Thoracic Aortic Aneurysms, and Penetrating Atherosclerotic Ulcers
Interventions
Relay Thoracic Stent-Graft, Open Repair
Device · Procedure
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 31, 2026, 9:35 AM EDT
Not listed Not applicable Interventional

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

NCT00238342
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer
Interventions
proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy
Genetic · Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
107
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Burbank, California + 80 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Oct 31, 2026, 9:35 AM EDT